Home page

The Fasting Hyperglycaemia Study (FHS) was a six-year, prospective, randomised, placebo-controlled study in subjects who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L and were thought to be at risk of developing diabetes. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes can be delayed or prevented using an insulin secretagogue (sulphonylurea) or reinforced healthy living advice.

• Principal Investigator: Professor Rury Holman
  
  
• ISRCTN number: ISRCTN
  

News

FHS Office, Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857240   Fax: +44 (0)1865 857241     Email: dtu@dtu.ox.ac.uk

Home | Freedom of Information | Privacy Policy | Copyright | Accessibility | OCDEM | NDM | Oxford University